The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000469314
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
21/01/2026
Date registered
Help: Date registered
16/04/2026
Date last updated
Help: Date last updated
16/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/04/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
An Early Feasibility Study of Neuromodulation therapy for Obstructive Sleep Apnea (OSA)
Scientific title
An Early Feasibility Study of Neuromodulation therapy for Obstructive Sleep Apnea (OSA) in Participants 22 years and older
Additional trial identifiers [1] 316319 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Obstructive Sleep Apnea (OSA) 340378 0
Condition category
Condition code
Respiratory 336582 336582 0 0
Sleep apnoea

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
: An implantable hypoglossal nerve stimulation system consisting of an Implantable Pulse Generator (IPG) and stimulation lead cuff to maintain airway patency during sleep will be implanted by an ENT or trained surgeon. The IPG will be implanted in the upper chest region while the stimulation lead will be implanted in the neck region. The cuff itself is wrapped around the hypoglossal nerve. Stimulation parameters will be programmed to reflect the current standard of care for sleep apnea (e.g. Pulse Amplitude 0.0 - 4.5mA, Pulse Width 62µs, Pulse Frequency 33Hz). The implant will provide therapy every night for the duration of sleep for 24 months. Participants will complete questionnaires to assess changes in sleep quality and impact on quality of life
Intervention code [1] 332979 0
Treatment: Devices
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344132 0
Incidence of device or procedure related serious adverse events (SAEs). This will be assessed as a composite outcome.
Timepoint [1] 344132 0
12 months post-implantation and 24 months post-implantation. At implant, and month 2, month 3/4, month 6, month 9, month 12, month 15, month 18, month 21, month 24.
Secondary outcome [1] 456837 0
Evaluation of the changes in the Apnea-Hypopnea Index (AHI).
Timepoint [1] 456837 0
From baseline to month 6 and month 12. Frequency of assessment is monthly.
Secondary outcome [2] 456838 0
Changes in sleepiness
Timepoint [2] 456838 0
From baseline to month 12 (monthly)
Secondary outcome [3] 457232 0
Evaluation of the changes in Oxygen Desaturation Index (ODI) at 4%.
Timepoint [3] 457232 0
From baseline to month 6 and month 12. Frequency of assessment is monthly.
Secondary outcome [4] 457233 0
Changes in fatigue
Timepoint [4] 457233 0
From baseline to month 12 (monthly)
Secondary outcome [5] 457234 0
Changes in sleep related impairment
Timepoint [5] 457234 0
From baseline to month 12 (monthly)
Secondary outcome [6] 457235 0
Changes in sleep quality
Timepoint [6] 457235 0
From baseline to month 12 (daily)

Eligibility
Key inclusion criteria
- Age 22 years or older at the time of implant
- English language proficiency
- BMI greater than or equal to 35 kg/m2
- Moderate-to-severe OSA (AHI 15–65 events/h using greater than or equal to 4% oxygen desaturation criteria, sleep efficiency greater than or equal to 75%, central/mixed greater than 25%)
- Refused, failed, or intolerant to CPAP or oral appliance therapy
- Willing and able to provide informed consent and comply with visits
Minimum age
22 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion Criteria (Protocol):
- Severe uncontrolled respiratory, cardiac, or renal disease
- Other implanted devices (pacemaker, ICD, VNS)
- Significant comorbidities (neuromuscular disease, hypoglossal nerve palsy, psychiatric disease)
- Substance/alcohol abuse within 3 years
- Primary insomnia (ISI greater than or equal to 20)
- PSG criteria outside AHI 15–65 (using greater than or equal to 4% oxygen desaturation criteria) or T-90 greater than 20%

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC

Funding & Sponsors
Funding source category [1] 320919 0
Charities/Societies/Foundations
Name [1] 320919 0
Not-for-profit sponsor The Alfred E. Mann Foundation for Scientific Research (HuMannity Medtec)
Country [1] 320919 0
United States of America
Primary sponsor type
Charities/Societies/Foundations
Name
The Alfred E. Mann Foundation for Scientific Research (HuMannity Medtec)
Address
Country
United States of America
Secondary sponsor category [1] 323614 0
Other Collaborative groups
Name [1] 323614 0
Avania Pty Ltd
Address [1] 323614 0
Country [1] 323614 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319459 0
Bellberry Human Research Ethics Committee B
Ethics committee address [1] 319459 0
Ethics committee country [1] 319459 0
Australia
Date submitted for ethics approval [1] 319459 0
10/09/2025
Approval date [1] 319459 0
21/11/2025
Ethics approval number [1] 319459 0
HREC2025-08-1360

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147386 0
Dr Prof. Danny Eckert
Address 147386 0
Adelaide Institute for Sleep Health, Flinders University Mark Oliphant Building 5 Laffer Drive, Bedford Park SA 5042 GPO Box 2100 Adelaide SA 5001
Country 147386 0
Australia
Phone 147386 0
+61 8 7421 9780
Fax 147386 0
Email 147386 0
Contact person for public queries
Name 147387 0
Dennis Jenkins
Address 147387 0
The Alfred E. Mann Foundation for Scientific Research (HuMannity Medtec) 25134 Rye Canyon Loop Valencia, California 91355
Country 147387 0
United States of America
Phone 147387 0
+1 661 714 2637
Fax 147387 0
Email 147387 0
Contact person for scientific queries
Name 147388 0
Prof. Danny Eckert
Address 147388 0
Adelaide Institute for Sleep Health, Flinders University Mark Oliphant Building 5 Laffer Drive, Bedford Park SA 5042 GPO Box 2100 Adelaide SA 5001
Country 147388 0
Australia
Phone 147388 0
+61 8 7421 9780
Fax 147388 0
Email 147388 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.